Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pharmacoepidemiol Drug Saf. 2024 Jan;33(1):e5727. doi: 10.1002/pds.5727. Epub 2023 Nov 20.
Rigorously conducted pharmacoepidemiologic research requires methodologically complex study designs and analysis yet evaluates problems of high importance to patients and clinicians. Despite this, participation in and mechanisms for stakeholder engagement in pharmacoepidemiologic research are not well-described. Here, we describe our approach and lessons learned from engaging stakeholders, of varying familiarity with research methods, in a rigorous multi-year pharmacoepidemiologic research program evaluating the comparative effectiveness of diabetes medications.
We recruited 5 patient and 4 clinician stakeholders; each was compensated for their time. Stakeholders received initial formal training in observational research and pharmacoepidemiologic methods sufficient to enable contribution to the research project. After onboarding, stakeholder engagement meetings were held virtually, in the evening, 2-3 times annually. Each was approximately 90 min and focused on 1-2 specific questions about the project, with preparatory materials sent in advance.
Stakeholder meeting attendance was high (89%-100%), and all stakeholders engaged with the research project, both during and between meetings. Stakeholders reported positive experiences with meetings, satisfaction, and interest in the research project and its findings, and dedication to the success of the project's goals. They affirmed the value of receiving materials to review in advance and the effectiveness of a virtual platform. Their contributions included prioritizing and suggesting research questions, optimizing written evidence briefs for a lay audience, and guidance on broader topics such as research audience and methods of dissemination.
Stakeholder engagement in pharmacoepidemiologic research using complex study designs and analysis is feasible, acceptable, and positively impacts the research project.
严格进行药物流行病学研究需要方法复杂的研究设计和分析,但评估的问题对患者和临床医生非常重要。尽管如此,利益相关者参与药物流行病学研究的机制和方法并没有得到很好的描述。在这里,我们描述了我们的方法,并从参与研究中获得了经验教训,这些研究参与者对研究方法的熟悉程度各不相同,该研究是一项严格的、多年的药物流行病学研究项目,评估了糖尿病药物的比较效果。
我们招募了 5 名患者利益相关者和 4 名临床医生利益相关者;每位参与者都获得了与其时间相对应的报酬。利益相关者接受了初步的、正式的观察性研究和药物流行病学方法培训,以使其能够为研究项目做出贡献。入职后,通过虚拟方式,在晚上,每年举行 2-3 次利益相关者会议。每次会议大约 90 分钟,重点讨论项目中的 1-2 个具体问题,并提前发送预备材料。
利益相关者会议的出席率很高(89%-100%),所有利益相关者都在会议期间和会议之间参与了研究项目。利益相关者报告了对会议的积极体验、满意度和对研究项目及其发现的兴趣,以及对项目目标成功的投入。他们肯定了提前收到材料进行审查的价值,以及虚拟平台的有效性。他们的贡献包括确定和建议研究问题、优化针对非专业读者的书面证据摘要,以及提供更广泛的主题的指导,如研究受众和传播方法。
使用复杂的研究设计和分析进行药物流行病学研究中的利益相关者参与是可行的、可接受的,并且可以积极影响研究项目。